Key statistics dashboard for Neurocrine Biosciences, Inc. (NBIX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages.
Stock Data
| Price | $144.21 |
| Market Cap | $14.5B |
| Enterprise Value | $14.57B |
| Beta | 0.35 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 20.46 |
| Price / Book | 3.94 |
| P/S | 4.30 |
| EV/EBITDA | 15.87 |
| EV/Sales | 4.32 |
| EV/FCF | 16.74 |
| P/FCF | 16.66 |
| Earnings Yield | 4.84% |
| FCF Yield | 6.00% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 97.97% |
| EBIT Margin | 25.81% |
| EBITDA Margin | 27.21% |
| Operating Margin | 23.38% |
| Net Margin | 20.91% |
| Return on Equity | 21.13% |
| Return on Assets | 13.16% |
| Return on Invested Capital | 13.20% |
| Return on Capital Employed | 17.59% |
Financial Health
| Current Ratio | 1.87 |
| Quick Ratio | 1.75 |
| Cash Ratio | 0.38 |
| Debt / Equity | 0.11 |
| Debt / Assets | 7.50% |
| Net Debt / EBITDA | 0.08 |
| Interest Coverage | 272.03 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 7.80 |
Per-Share Data
| Revenue per share | 33.40 |
| Book Value per share | 36.57 |
| Cash per share | 3.86 |
| FCF per share | 8.62 |
| Tangible Book Value per share | 9.57 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 32 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 37 |
| Avg rating (1-5) | 0.86 |
Related companies: COO · ELAN · ICLR · RDY · SMMT · SNN
Explore sector: Healthcare · Biotechnology
More sections of NBIX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks